NJ-FREYR-SOLUTIONS
13.8.2024 07:50:33 CEST | Business Wire | Press release
Freyr, a premier global Regulatory solutions and services provider, proudly announces its distinguished placement as a Leader in the esteemed Everest Group Life Sciences Regulatory and Medical Affairs Operations PEAK Matrix® Assessment 2024. Freyr has emerged as the leader from this comprehensive evaluation of over twenty (20) global service providers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240731962821/en/
Everest Group Life Sciences and Medical Affairs Operations PEAK Matrix® Assessment 2024 (Graphic: Business Wire)
The PEAK Matrix® offers an impartial, data-driven evaluation of service and technology providers, categorizing them as Leaders, Major Contenders, or Aspirants based on their overall capabilities and market impact.
“In the rapidly evolving regulatory landscape, enterprises face a myriad of challenges, such as navigating complex compliance frameworks, ever-changing regulations, and diverse geographical needs. Consequently, enterprises are increasingly reliant on external service providers with specialized knowledge and technological expertise to manage these complexities," says Lloyd Fernandes, Practice Director at Everest Group. He added, "Freyr's extensive market presence and robust affiliate network, bolstered by its localized expertise, make it adept at navigating diverse regulatory environments. Furthermore, its comprehensive portfolio of technological solutions built on the AI first Freya Fusion platform, along with its dedicated centers of excellence, enable it to effectively address clients' digitization and efficiency demands. These strengths have contributed to its Leader positioning in Everest Group's Regulatory and Medical Affairs Operations PEAK Matrix Assessment 2024."
Suren Dheenadayaalan, CEO of Freyr Solutions, expressed his delight, stating, "Securing the Leader position in the Everest Group Life Sciences Regulatory and Medical Affairs Operations PEAK Matrix® Assessment is a significant milestone for Freyr. This recognition reaffirms our commitment throughout the Regulatory value chain in the Life Sciences sector. We take pride in being recognized as a reliable global Regulatory partner and remain committed to fostering innovation while surpassing compliance standards in the intricate Regulatory landscape."
Rajiv Rangan, Co-founder of Freyr Solutions, added, "This acknowledgment from the prestigious Everest Group underscores our continued dedication to Regulatory services & solution excellence spanning over decade+ years. On behalf of the founding team of Freyr, I extend our sincere and heartfelt gratitude to our global colleagues and customers for their continued and invaluable support, without which this accomplishment would not have been possible."
About Freyr
Freyr Solutions provides global Regulatory solutions, with 2100+ experts supporting 1550+ customers in 120+ countries.
"Discover how Freyr leads the way in regulatory excellence—visit our website for more details. Freyr Solutions"
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731962821/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G Nfl Blood Assay17.3.2026 07:00:00 CET | Press release
H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Europe N.V. has obtained a CE Certificate of the Lumipulse G NfL Blood assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Neurofilament light chain (NfL) in plasma and serum. “While our assay menu already features many powerful disease-specific biomarkers, NfL marks a major breakthrough: our first CE-marked blood test that empowers clinicians with insights across a wide range of neurological disorders,” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “We are excited to bring this test to our customers, further expanding our comprehensive portfolio of fully automated neurological disease testing solutions on the LUMIPULSE G platform. We continue to partner with organizations and clinical experts across the wor
H2SITE Appoints Javier Cavada as New Chairman of the Board of Directors17.3.2026 07:00:00 CET | Press release
H2SITE, a technology company delivering hydrogen production and separation solutions, announces the appointment of Javier Cavada as the new Chairman of the Board of Directors. Javier joins H2SITE at a strategic phase of accelerated industrial deployment and scale-up of its hydrogen solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316654723/en/ With more than 25 years of international leadership in the energy and industrial sectors, Javier brings extensive experience in industrialising complex technologies, building high-performance organisations, and scaling large-scale energy platforms. He currently serves as President and Chief Executive Officer of Mitsubishi Power EMEA. His track record also includes serving as CEO and President of Highview Power, as well as spending 17 years at Wärtsilä Corporation, where he held senior executive roles including President of the Energy division and a member of the global Exec
AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies17.3.2026 07:00:00 CET | Press release
Galderma will present nine posters spanning its full aesthetics portfolio at AMWC 2026, highlighting the regenerative benefits of Sculptra®, the long-lasting efficacy of Restylane®, and the advanced clinical performance of Relfydess® (RelabotulinumtoxinA) 1-9 The data reinforce Galderma’s future-focused approach to innovation, addressing emerging patient needs from menopause‑related skin changes to rising interest in body injectables and regenerative treatments A series of symposia and Masterclasses will further highlight Galderma’s leadership in aesthetics, showcasing how the portfolio supports complex patient profiles and evolving global trends Galderma (SIX: GALD) will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scientific data across its aesthetics portfolio, alongside three symposia, and multiple Masterclasses and Meet‑the‑Expert sessions, all highlighting the expanding benefits of Sculptra, R
Miro Announces Asia Hub in Singapore to Accelerate Growth Across the Region and Bring AI Collaboration to New Markets17.3.2026 02:00:00 CET | Press release
AI Innovation Workspace perfectly placed to help organisations maximise AI investment and accelerate innovation Miro®, the AI Innovation Workspace for teams, today announced plans to expand its operations in Asia, supporting organisations across the region in their AI transformation journey. Miro is investing in people, resources, and infrastructure as it targets growth in key markets, including Singapore, India, South Korea, and other Southeast Asia countries. As the global innovation centre of gravity shifts toward Asia – where R&D spending reached 45% of global investment in 2024 – the organisations leading this charge need tools and platforms built for the complexity and pace of modern innovation and collaboration. Miro's AI-powered innovation workspace is uniquely positioned to support this moment. Miro gives organisations the shared context layer they need to move from insight to execution faster than ever before. For Asia's most ambitious innovators, where speed-to-market and cr
IQM and Zurich Instruments Launch Real-Time Quantum Error Correction Demonstrator with NVIDIA NVQLink16.3.2026 22:24:00 CET | Press release
The demonstrator being built in this project delivers a clear path toward scalable and fault-tolerant quantum computers. The joint project integrates IQM’s superconducting quantum processor, Zurich Instruments’ ZQCS Quantum Control System, with the NVIDIA NVQLink platform to enable real-time error correction. This initiative establishes a foundation for standardized enterprise-ready quantum systems, and datacenter deployment. Today, IQM Quantum Computers and Zurich Instruments announce a joint project to build and operate a real-time quantum error correction (QEC) demonstrator, enabled by the NVIDIA NVQLink platform. This project marks a significant milestone toward scalable and fault-tolerant quantum computing designed for enterprise and datacenter deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316511715/en/ IQM and Zurich Instruments launch real-time quantum error correction demonstrator with NVIDIA NVQLink
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom